Presenter announces pharma price pledge and FDA approval of Regeneron's Otarminy

A presenter announced that "17 of the world's largest pharmaceutical companies representing 80% of the branded drug market have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world," and said the U.S. Food and Drug Administration had approved Regeneron's new gene therapy, Otarminy, to treat a rare disease that causes deafness.

The presenter introduced 2-year-old Travis Smith, saying the child "was born deaf," and used Travis as an example of who could benefit from the newly approved treatment. The presenter also offered a personal illustration: "My son went from having absolutely no personality and he couldn't connect with anybody, and now he loves music and he's able to understand me and I can tell him how much I love him," the presenter said.

Why this matters: If implemented as described, the pricing pledge would affect access to a range of prescription drugs for U.S. patients, and the approval of a gene therapy for a deafness-causing condition could expand treatment options for affected children. The presenter framed both announcements as linked efforts to lower drug costs and increase access.

Details provided in the remarks: The presenter said 17 companies representing 80% of the branded drug market had made the pricing commitment and named Regeneron's Otarminy as an FDA-approved gene therapy for a rare form of deafness. He said there is an "unprecedented corporate commitment" to provide the therapy free to "all the children in the United States who can benefit." The presenter did not identify which company or companies would provide the free doses, how distribution will be organized, or a timeframe for those deliveries.

Direct quotes from the remarks include: "17 of the world's largest pharmaceutical companies representing 80% of the branded drug market have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world," and "The FDA has just approved a new drug from Regeneron called Otarminy, a gene therapy curing a rare disease that causes deafness." The article retains the speaker's original phrasing but attributes claims about company commitments and market share to the presenter, as those claims were made in the remarks and not independently verified in the transcript.

What was not said: The presenter did not list the participating companies, specify which companies would make Otarminy available at no cost, give enrollment or eligibility procedures, or provide a schedule for when free doses would be available. No additional sponsors, federal funding sources, or regulatory conditions for distribution were named in the remarks.

Next steps and outlook: The announcement, as delivered, is an initial statement of intent and an FDA regulatory milestone; further implementation details and confirmations (which companies will participate, distribution logistics and eligibility) were not provided during the remarks.